192 related articles for article (PubMed ID: 26764971)
1. Servier's pipeline in oncology: moving from research to patients.
Therasse P; Abastado JP
Future Oncol; 2016 Mar; 12(5):589-94. PubMed ID: 26764971
[No Abstract] [Full Text] [Related]
2. The Servier oncology pipeline in 2017.
Therasse P; Perron B; Novack SA; Abastado JP
Future Oncol; 2017 Jul; 13(17):1527-1536. PubMed ID: 28427281
[TBL] [Abstract][Full Text] [Related]
3. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
Zinzani PL; Corradini P; Martelli M; Minotti G; Oliva S; Spina M; Barosi G; Tura S
Eur J Haematol; 2016 Dec; 97(6):554-561. PubMed ID: 27124765
[TBL] [Abstract][Full Text] [Related]
4. Companies waver in efforts to target transforming growth factor beta in cancer.
Garber K
J Natl Cancer Inst; 2009 Dec; 101(24):1664-7. PubMed ID: 19933941
[No Abstract] [Full Text] [Related]
5. Lymphoma researchers in search of molecular targets.
Friedrich MJ
J Natl Cancer Inst; 2010 Jul; 102(14):1000-1. PubMed ID: 20616351
[No Abstract] [Full Text] [Related]
6. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
7. NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Landells LJ; Prescott C; Hay N; Sutcliffe F; Stevens A
Lancet Oncol; 2014 Apr; 15(4):381-2. PubMed ID: 24818252
[No Abstract] [Full Text] [Related]
8. Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?
Witkowska M; Smolewski P; Majchrzak A; Robak T
Expert Opin Drug Discov; 2016 Nov; 11(11):1033-1045. PubMed ID: 27569454
[TBL] [Abstract][Full Text] [Related]
9. Beyond ipilimumab: new approaches target the immunological synapse.
Garber K
J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695
[No Abstract] [Full Text] [Related]
10. An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Hübel K
Expert Opin Pharmacother; 2018 Nov; 19(16):1829-1834. PubMed ID: 30269614
[TBL] [Abstract][Full Text] [Related]
11. The role of alisertib in treatment of peripheral T-cell lymphomas.
Gallop-Evans E
Future Oncol; 2015 Sep; 11(18):2515-24. PubMed ID: 26344156
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacologic characteristics and clinical activity of human rituximab anti-CD20 monoclonal antibody].
Varaldo R; Gobbi M
Ann Ital Med Int; 2003; 18(3):182-7. PubMed ID: 14621431
[No Abstract] [Full Text] [Related]
13. Monoclonal antibodies for medical oncology: a few critical perspectives.
Belda-Iniesta C; Ibáñez de Cáceres I; de Castro J
Clin Transl Oncol; 2011 Feb; 13(2):84-7. PubMed ID: 21324795
[TBL] [Abstract][Full Text] [Related]
14. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.
Martin P; Furman RR; Coleman M; Leonard JP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5636s-5642s. PubMed ID: 17875800
[TBL] [Abstract][Full Text] [Related]
15. Combination therapies in oncology.
Webster RM
Nat Rev Drug Discov; 2016 Feb; 15(2):81-2. PubMed ID: 26837588
[No Abstract] [Full Text] [Related]
16. Pixantrone: merging safety with efficacy.
Papadatos-Pastos D; Pettengell R
Expert Rev Hematol; 2013 Feb; 6(1):25-33. PubMed ID: 23373776
[TBL] [Abstract][Full Text] [Related]
17. Emerging immunotherapy in pediatric lymphoma.
Erker C; Harker-Murray P; Burke MJ
Future Oncol; 2016 Jan; 12(2):257-70. PubMed ID: 26616565
[TBL] [Abstract][Full Text] [Related]
18. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):4-6. PubMed ID: 18998258
[No Abstract] [Full Text] [Related]
19. Development trends for monoclonal antibody cancer therapeutics.
Reichert JM; Valge-Archer VE
Nat Rev Drug Discov; 2007 May; 6(5):349-56. PubMed ID: 17431406
[TBL] [Abstract][Full Text] [Related]
20. Clinical investigations in aggressive non-Hodgkin lymphoma.
Jonathan F
Clin Adv Hematol Oncol; 2008 Sep; 6(9):7-8. PubMed ID: 18998259
[No Abstract] [Full Text] [Related]
[Next] [New Search]
